Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CMPX)

Historical Holders from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CMPX on Nasdaq
Shares outstanding
176,391,745
Price per share
$5.37
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
151,052,849
Total reported value
$528,694,287
% of total 13F portfolios
0%
Share change
+42,790,470
Value change
+$149,920,660
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
124
Price from insider filings
$5.17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CMPX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 10% +1.9% $60,117,785 +$12,881,057 17,176,510 +27% TANG CAPITAL MANAGEMENT, LLC 30 Sep 2025
ORBIMED ADVISORS LLC 8.9% -19% $49,921,580 15,219,994 0% ORBIMED ADVISORS LLC 13 Aug 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 8.2% +60% $46,251,802 +$22,801,464 14,101,159 +97% Suvretta Capital Management, LLC 13 Aug 2025
Vivo Opportunity Fund Holdings, L.P. 5.1% $31,485,926 8,995,979 Vivo Opportunity Fund Holdings, L.P. 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 5.1% $30,625,000 8,750,000 BVF PARTNERS L P/IL 22 Oct 2025
Commander Aggregator, LP 4.5% $25,545,132 7,788,150 Commander Aggregator, LP 14 Aug 2025
BlackRock, Inc. 4.6% -8% $12,797,976 -$977,254 6,398,988 -7.1% BlackRock, Inc. 30 Jun 2025
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.4% $10,191,177 5,994,810 Adage Capital Management, L.P. 31 Dec 2024
MPM BioImpact LLC 4.1% -35% $14,618,513 -$7,658,017 5,622,505 -34% MPM BioImpact LLC 30 Jun 2025
As of 30 Sep 2025, Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CMPX) has 124 institutional shareholders filing 13F forms. They hold 151,052,849 shares. of 176,391,745 outstanding shares (86%) .

Top 25 institutional shareholders own 80% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 9.5% 16,811,963 +25% 2.3% $58,841,871
ORBIMED ADVISORS LLC 8.6% 15,219,994 0% 1.3% $53,269,979
SUVRETTA CAPITAL MANAGEMENT, LLC 8% 14,101,159 +97% 1.5% $49,354,057
Blackstone Inc. 5.6% 9,840,108 -1.8% 0.15% $34,440,379
Vivo Capital, LLC 5.4% 9,545,466 +58% 2.7% $33,409,131
ENAVATE SCIENCES GP, LLC 4.4% 7,788,150 0% 8.3% $27,258,525
BlackRock, Inc. 4.2% 7,370,747 +15% 0% $25,797,616
VANGUARD GROUP INC 4% 7,062,799 +46% 0% $24,719,798
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.9% 5,186,500 +17% 0.03% $18,152,750
MPM BIOIMPACT LLC 2.9% 5,075,970 -9.7% 2.9% $17,765,895
BVF INC/IL 2.7% 4,750,000 0.67% $16,625,000
Rock Springs Capital Management LP 2.5% 4,474,702 -9.8% 0.92% $15,661,457
FMR LLC 2.3% 4,137,562 +0.07% 0% $14,481,467
MILLENNIUM MANAGEMENT LLC 1.8% 3,237,572 +280% 0.01% $11,331,502
STATE STREET CORP 1.8% 3,106,513 +58% 0% $10,872,796
GEODE CAPITAL MANAGEMENT, LLC 1.7% 2,944,469 +27% 0% $10,307,859
SILVERARC CAPITAL MANAGEMENT, LLC 1.6% 2,833,988 +127% 1.4% $9,918,958
Balyasny Asset Management L.P. 1.6% 2,826,362 0.02% $9,892,267
Blue Owl Capital Holdings LP 1.5% 2,591,525 0% 2.8% $9,070,338
RTW INVESTMENTS, LP 1.4% 2,500,000 0.11% $8,750,000
Logos Global Management LP 1.2% 2,050,000 0.71% $7,175,000
Sofinnova Investments, Inc. 1.2% 2,028,886 0.44% $7,101,101
JPMORGAN CHASE & CO 1.1% 1,999,278 -5.9% 0% $6,997,474
ROYAL BANK OF CANADA 0.96% 1,700,927 +1025% 0% $5,953,000
Monashee Investment Management LLC 0.71% 1,250,000 +658% 2.2% $4,375,000

Institutional Holders of Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CMPX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 106,562 $572,156 -$229,538 537.43% 2
2025 Q3 151,052,849 $528,694,287 +$149,920,660 350% 124
2025 Q2 108,253,035 $281,458,749 +$738,244 260% 103
2025 Q1 108,444,414 $206,048,165 +$13,824,950 190% 107
2024 Q4 101,374,021 $146,995,622 +$1,180,772 145% 92
2024 Q3 92,186,861 $169,597,428 +$881,084 184% 79
2024 Q2 92,861,661 $93,412,701 -$5,271,745 100% 81
2024 Q1 94,552,324 $187,180,098 +$18,216,230 198% 77
2023 Q4 39,556 $61,707 156% 1
2023 Q3 89,720,729 $176,713,174 -$1,697,932 197% 76
2023 Q2 90,478,972 $287,651,572 +$28,650,120 318% 72
2023 Q1 81,516,748 $266,518,963 +$1,801,941 327% 72
2022 Q4 79,833,267 $401,391,571 +$78,794,072 503% 54
2022 Q3 63,858,418 $145,631,000 +$8,154,660 228% 36
2022 Q2 61,892,616 $163,922,000 +$665,885 265% 31
2022 Q1 62,376,106 $85,353,000 -$4,074,808 137% 33
2021 Q4 63,567,962 $201,611,000 +$198,091,738 317% 37